Amgen: Osteoporosis, Postmenopausal trials

The registry lists 21 Osteoporosis, Postmenopausal studies with Amgen as lead sponsor. 0 are open to participants now and 20 have results posted.

Phase 1 1Phase 2 4Phase 3 11Phase 4 2No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.CompletedNCT06079476Phase 4Results posted
• A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for OsteoporosisCompletedNCT03432533Phase 3Results posted
• A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean Women With OsteoporosisCompletedNCT02791516Phase 3Results posted
• A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With OsteoporosisCompletedNCT02157948Phase 3Results posted
• A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With OsteoporosisCompletedNCT02016716Phase 3Results posted
• Efficacy, Safety and Tolerability of Romosozumab in the Treatment of Japanese Women With Postmenopausal OsteoporosisCompletedNCT01992159Phase 2Results posted
• An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal WomenCompletedNCT01796301Phase 3Results posted
• Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With OsteoporosisCompletedNCT01732770Phase 4Results posted
• Observational Study of Denosumab (Prolia®) in Postmenopausal Women With OsteoporosisCompletedNCT01668589Results posted
• Prospective Observational Study to Describe Characteristics and Management of Patients Treated With Denosumab (Prolia®) in Routine Clinical PracticeCompletedNCT01652690Results posted
• Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With OsteoporosisCompletedNCT01575834Phase 3Results posted
• The Effects of Denosumab on the Pharmacokinetics (PK) of MidazolamCompletedNCT01221727Phase 1Results posted
• A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly BisphosphonatesCompletedNCT00936897Phase 3Results posted
• Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral DensityCompletedNCT00896532Phase 2Results posted
• A High-resolution Peripheral Quantitative Computed Tomography Study in Postmenopausal Women Previously Treated With DenosumabCompletedNCT00890981Phase 3Results posted
• A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With DenosumabCompletedNCT00887965Phase 2Results posted
• Study of Transitioning From Alendronate to DenosumabCompletedNCT00377819Phase 3Results posted
• A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral DensityCompletedNCT00293813Phase 2Results posted
• Study to Evaluate AMG 162 in the Prevention of Postmenopausal OsteoporosisCompletedNCT00091793Phase 3Results posted
• A Study to Evaluate Denosumab in the Treatment of Postmenopausal OsteoporosisCompletedNCT00089791Phase 3Results posted
• Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia® in FranceCompletedNCT02347865